Replimune Group (NASDAQ:REPL) Insider Konstantinos Xynos Sells 16,198 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Konstantinos Xynos sold 16,198 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $21.60, for a total value of $349,876.80. Following the completion of the transaction, the insider owned 208,017 shares in the company, valued at $4,493,167.20. This represents a 7.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 0.6%

REPL traded up $0.12 during midday trading on Wednesday, hitting $19.81. 2,130,078 shares of the company’s stock traded hands, compared to its average volume of 3,489,130. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90. The company has a market cap of $1.88 billion, a PE ratio of -7.10 and a beta of 0.93. The stock’s fifty day simple moving average is $15.10 and its 200-day simple moving average is $10.23. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $23.54.

Replimune Group (NASDAQ:REPL – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.24. As a group, equities analysts anticipate that Replimune Group, Inc. will post -2.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Replimune Group in the second quarter valued at about $99,171,000. Montanova Capital LLC increased its stake in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares during the period. Marshall Wace LLP acquired a new position in shares of Replimune Group during the 3rd quarter worth about $50,516,000. Opaleye Management Inc. acquired a new position in shares of Replimune Group during the 2nd quarter worth about $15,332,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after purchasing an additional 20,742 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Friday, August 7th. Leerink Partners boosted their price target on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Replimune Group in a research note on Wednesday, November 4th. Finally, JPMorgan Chase & Co. increased their price objective on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.17.

Get Our Latest Stock Report on Replimune Group

About Replimune Group

(Get Free Report)

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.

Further Reading

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.